Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Centocor Inc.

(CNTO)

David Crossen of UBS Securities repeated a "buy." He said the positive reception at the American Heart Association meeting of

ReoPro

, CNTO's

GPIIb/IIIa

inhibitor to block platelet aggregation, suggests the drug could become standard therapy in a high percentage of angioplasty and other procedures.

Read the full 498 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE